Daiichi Sankyo Bets $1.9 Billion on Global Cancer Drug Production

Japanese drugmaker Daiichi Sankyo will invest $1.9 billion to build new manufacturing lines. The expansion targets key markets in China, the United States, and Europe. The move prepares for the expected high demand for its new cancer treatments. These include a promising drug developed with Merck & Co. The investment will boost production capacity for complex antibody-based therapies. A company spokesperson stated the funds will secure a stable supply of these advanced drugs worldwide. This large-scale investment highlights the growing global competition in the oncology, or cancer drug, market. It ensures Daiichi Sankyo can meet future orders as its new treatments await regulatory approval.